Frustrations Of A Ceramicist

While nuclear magnetic resonance (NMR) equipment represents the biggest market for superconductivity technology, more than 60% of the current technology is applied there, the flurry of activity in the new high-temperature superconductors has not yet translated to state-of-the art changes in NMR. In fact, researchers face three major hurdles in the race to realize the potential of these promising ceramics. For most of the past 15 months, attention has centered on YBa2Cu3O7 usually referred

Written byRoger Poeppel
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

While nuclear magnetic resonance (NMR) equipment represents the biggest market for superconductivity technology, more than 60% of the current technology is applied there, the flurry of activity in the new high-temperature superconductors has not yet translated to state-of-the art changes in NMR.

In fact, researchers face three major hurdles in the race to realize the potential of these promising ceramics.

For most of the past 15 months, attention has centered on YBa2Cu3O7 usually referred to as "1-2-3," a ceramic that becomes superconducting below 93 K. Exciting as the research has been, the material poses considerable impediments to commercial users. First, 1-2-3 in most bulk samples has a relatively low capacity to carry current (critical current density). It is difficult to create and, perhaps worst of all, shows low strength and little ductility.

The low critical current density comes from a phenomenon known as “weak-link” behavior. In a polycrystalline sample, individual ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies